We therefore administered the CDK7 inhibitor ICEC0942 (CDK7i) in combination with palbociclib during the second cycle of treatment to establish if inhibition of an additional CDK could inhibit growth of tumours that were no longer responding to palbociclib. The gene discussed is CDK7; the disease is neoplasm.